AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell

AbCellera Biologics Inc. remains rated Hold, with valuation concerns outweighing near-term pipeline catalysts despite recent share price volatility. ABCL635, targeting hot flashes, is advancing to a Phase 2 trial with a key data readout expected in Q3, potentially derisking the program. Partnered and proprietary pipeline programs lack momentum, with most assets preclinical or awaiting external funding, limiting near-term revenue visibility.

Seeking Alpha • Jun 9, 2026

Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Jun 8, 2026

AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 5, 2026

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Victor Sandor to its Board of Directors.

Business Wire • Jun 5, 2026

AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam

AbCellera Biologics NASDAQ: ABCL is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech's pipeline and lead clinical program.

MarketBeat • Jun 4, 2026

Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?

Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

Zacks Investment Research • Jun 1, 2026

After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright

From a technical perspective, AbCellera Biologics Inc. (ABCL) is looking like an interesting pick, as it just reached a key level of support. ABCL's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Zacks Investment Research • May 29, 2026

Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • May 22, 2026

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.

24/7 Wall Street • May 18, 2026

AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 14, 2026